Eastgate Biotech Corp.
ETBI · OTC
9/30/2017 | 6/30/2017 | 3/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Revenue | $23 | $115 | $0 | -$94 |
| % Growth | -79.8% | – | 100% | – |
| Cost of Goods Sold | $92 | $57 | $0 | -$14 |
| Gross Profit | -$69 | $58 | $0 | -$80 |
| % Margin | -299.1% | 50.3% | – | 85.1% |
| R&D Expenses | $12 | $94 | $176 | $135 |
| G&A Expenses | $1,588 | $358 | $679 | $548 |
| SG&A Expenses | $1,664 | $436 | $739 | $493 |
| Sales & Mktg Exp. | $76 | $78 | $60 | -$55 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,652 | $530 | $915 | $628 |
| Operating Income | -$1,691 | -$472 | -$915 | -$707 |
| % Margin | -7,307.8% | -412.6% | – | 756% |
| Other Income/Exp. Net | $58 | -$242 | -$37 | -$227 |
| Pre-Tax Income | -$1,633 | -$715 | -$952 | -$935 |
| Tax Expense | -$27 | $0 | $0 | $0 |
| Net Income | -$1,633 | -$715 | -$952 | -$935 |
| % Margin | -7,057.2% | -624.3% | – | 999.2% |
| EPS | -0.002 | -0.001 | -0.003 | -0.003 |
| % Growth | -25% | 60% | 3.2% | – |
| EPS Diluted | -0.002 | -0.001 | -0.003 | -0.003 |
| Weighted Avg Shares Out | 1,111,741 | 574,213 | 318,070 | 304,796 |
| Weighted Avg Shares Out Dil | 1,111,741 | 574,213 | 318,070 | 304,796 |
| Supplemental Information | – | – | – | – |
| Interest Income | $58 | $0 | $0 | $0 |
| Interest Expense | $0 | $217 | $37 | $43 |
| Depreciation & Amortization | -$61 | $472 | $915 | -$41 |
| EBITDA | -$1,721 | $0 | -$915 | -$891 |
| % Margin | -7,439.6% | 0% | – | 953.2% |